Codexis, Inc. (NASDAQ:CDXS) Q4 2023 Earnings Call Transcript
Codexis, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.16.
Source: insidermonkey.com
Codex Hicap News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Codex Hicap. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Codex Hicap Today - Breaking & Trending Today
Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
28.02.2024 - Anticipate 2024 Product Revenue Growth of at Least 10% vs. 2023 Excluding Enzyme Sales Related to PAXLOVID Recently Announced Debt Financing Reinforces Strong Financial Position with Projected Runway Through Expected Positive Cash-flow Around End ...
Source: wallstreet-online.de
Codexis Shares Rise 19% on Licensing Agreement with Aldevron
By Denny Jacob Codexis shares were up 19% at $2.48 a day after it entered into an agreement with Aldevron. The stock is down about 47% on the year so far....
Source: marketwatch.com
Aldevron to acquire license to Codex HiCap RNA Polymerase
Aldevron has signed an agreement with US-based enzyme engineering company Codexis to acquire global exclusive license to Codex HiCap RNA Polymerase.
Industrial enzymes market size to grow by USD 2.19 billion between 2022 and 2027 | Increasing demand for food enzymes to drive the market growth
/PRNewswire/ -- The industrial enzymes market size is forecasted to increase by USD 2.19 billion from 2022 to 2027, at a CAGR of 6.26%, according to the recent...
Source: prnewswire.com